Skip to main content

Mantle Cell Lymphoma Research Initiative II (MCL2)

This program is now closed. Thank you for submitting your Letter of Intent.


The Mantle Cell Lymphoma Research Initiative II (MCL2) is a renewed and robust initiative to support targeted research to better understand disease mechanisms, develop more efficacious treatments and improve the outcome for MCL patients. Applications should address both transformative issues in MCL biology and promising new directions in MCL therapy.

Click here to see all our current supported projects tackling mantle cell lymphoma.

Please find all MCL2 program documents available for download here:


Program Description

LLS invites innovative and ambitious proposals that can lead to better treatments and cures for MCL. In particular, the goals of MCL2 are to better understand and develop therapeutic approaches for relapsed MCL. However, novel work focused on early disease intervention or improved risk stratification is of interest. LLS calls for the submission of creative proposals with the potential for high impact in MCL. Applications should address both transformative issues in MCL biology and promising new directions in MCL therapy. 


Key Topics of Interest

  • Understanding of the MCL tumor microenvironment and the properties of lymphoma cells responsible for disease relapse
  • Identifying the best treatment combinations based on solid preclinical rationale and data
  • Understanding and developing novel immunotherapies for MCL that have the potential to cure cancer
  • Identification and validation of novel targets in relapsed disease
  • Developing treatment approaches that replace cytotoxics with targeted therapies or immunotherapies that retain efficacy while reducing toxicity
  • Understanding the basis of resistance to existing and newly emerging therapies
  • Developing novel therapeutics, especially to targets that are unique to MCL and have previously been difficult to drug (e.g., transcription factors)
  • Developing additional, accurate animal models of the disease for critical testing of drugs
  • Developing predictive biomarkers of disease that can be used for early detection, prediction of treatment response, and to identify patients most likely to respond well to different treatments


Grant Funding Mechanisms

LLS is calling for inventive proposals that have the potential for high impact in the field of MCL. Research funding will provide support for two types of grants: Synergistic Team Award (STA) and Translational Grants (TRLs).

The Synergistic Team Award (STA) will support substantial, collaborative projects addressing a significant obstacle in understanding and treating MCL.

  • Research program led by a single program director (PD)
  • Research program must consist of 2-3 distinct but synergistic projects
  • Two-three independent research groups (PI’s) working collaboratively; one of the PI’s may be the PD. PI’s may be at the same or different institutions
  • Four years of funding
  • Major Go/No Go decision after two years
  • $3,000,000.00 total award; $750,000.00 per year
  • Indirect costs capped at 10% of total award amount
  • Annual site visit by LLS research staff
  • Two grants are planned to be awarded


The Translational Grants (TRL) will fund new and innovative research that advances laboratory discoveries toward clinical application.

  • Support for preclinical and/or biological research
  • Project led by a single PI
  • Three years of support
  • Third year of funding dependent on progress assessment at end of year two
  • $750,000.00 total award; $250,000.00 per year
  • Indirect costs capped at 10% of total award amount
  • Three grants are planned to be awarded


Maximum Duration and Value of each award mechanism

  Duration in Years Maximum Total Annual Costs Maximum Total for Duration of Award
STA 4 $750,000.00 $3,000,000.00
TRL 3 $250,000.00 $750,000.00


How to Apply

  • Please refer to the Guidelines & Instructions document above
  • Is this your first time applying for an LLS Research grant? You can get started by requesting a new account in the LLS Research Portal by clicking here.
  • Applicants must carefully read the program guidelines before beginning their applications.
  • See the table below for all the key dates and deadlines:

2022-2023 Application Key Dates for both awards

Phase Date
Call for Proposals October 10, 2022
Letter of Intent Due December 5, 2022, 3:00 PM (ET)
Notification of Full Application Invite December 15, 2022
Full Application Deadline February 24, 2023, 3:00 PM (ET)
Notification of Awards* May 2023
Grant Term Begins July 1, 2023



The above image was originally published in ASH Image Bank. Maryam Asif, Girish Venkataraman and Dan Arber. Mantle cell lymphoma with mantle zone pattern. ASH Image Bank. 2019;62363 © the American Society of Hematology.